Table of Contents
Themis Medicare share – About
The company’s primary focus lies in the production and distribution of bulk active pharmaceutical ingredients (APIs) sourced from both synthetic and biotech origins. Alongside APIs, the company also specializes in the manufacturing and marketing of bulk intermediates and various formulations.
Within the formulations segment, the company boasts an impressive lineup of medications that cater to different therapeutic needs. Notably, they produce anti-TB drugs to combat tuberculosis, anti-malarial drugs to fight against malaria, anti-cholesterol drugs to manage cholesterol levels, and pain management drugs to alleviate discomfort.
Click on the picture below to Open Demat account with Zerodha
Themis Medicare share – Stock highlights
The pharmaceutical company manufactures a diverse range of 190+ drugs, catering to approximately 20 different therapeutic areas. Their business revenue for FY23 is split as follows:
- API: 56%
- Hospital: 33%
- Trade: 11%
The company has established partnerships with renowned organizations such as Abbott, Baxter, Avecho, Bottu, Dina, Fidson, Gedeon Richter (promoter), Intas, Lupin, Mankind, Novartis, Pharmanova, Unilabs, Yuhan, and others.
In terms of geographic distribution, the company’s revenue split for FY23 is as follows:
- India: 59%
- Outside India: 41%
To support their operations, the company operates three manufacturing facilities located in Vapi, Gujarat; Hyderabad; and Haridwar. The Vapi unit in Gujarat is WHO-GMP certified and serves as an established bulk drug manufacturing facility.
Themis Medicare share – Stock Split
The company has recently announced 10-for-1 stock split i.e., for every one old share you held, you would receive Ten new shares with the adjusted lower face value. Here,
- Old face value: Rs. 10
- New face value: Rs. 1
In a stock split, the company increases the number of shares outstanding while simultaneously decreasing the stock’s price per share. This is usually done to make the stock more affordable to a wider range of investors and to improve liquidity.
The stock split will be effective on October 10, 2023.
Themis Medicare share – Financial parameters
- The company’s market capitalization is about ₹1,767 Crores.
- The current stock price stands at ₹1922, with a high/low range of ₹1972 to ₹875.
- The stock’s P/E ratio is at 30.6, while the book value is ₹369, and the dividend yield is 0.26%.
- The company exhibits a robust financial performance with an ROCE of 19.7% and an ROE of 17.3%.
- With a current face value of ₹10.00 and a debt-to-equity ratio of 0.27, it maintains a healthy financial structure.
- Pledged percentage of shares is 23.5%
Also read: Have a look at the following story:
Themis Medicare share – Technical parameters
The RSI(14) is currently at 78.0, indicating that the asset is in overbought territory.
The Stochastic Oscillator is at 87.5, suggesting that the asset may be nearing a short-term peak.
The CCI 20 stands at 224.7, indicating a strong bullish trend.
The Awesome Oscillator is at 120.6, which suggests that the market is currently experiencing strong upward momentum.
The Momentum Oscillator is at 243.2, indicating a highly bullish market sentiment.
The MACD(12, 26, 9) stands at 59.1, suggesting that the asset is currently in a mild bullish trend.
The Stochastic RSI is at 97.6, indicating that the asset is in overbought territory.
William is at -12.1, suggesting that the asset’s price is near the lower end of its range.
Lastly, the Ultimate Oscillator is at 60.0, which is indicative of a neutral market condition.
Here are the resistance and support levels for Themis Medicare:
Resistance:
- R1: 1973
- R2: 2034
- R3: 2097
Support:
- S1: 1858
- S2: 1795
- S3: 1738
Disclaimer:
This is not a stock recommendations. All efforts have been made to correctly represent facts and figures in the post. The website or its management is not responsible for any kind of losses arising out of Investing in equities. Investors must therefore exercise due caution while investing or trading in stocks. NSE Options.in or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing
